Advertisement
Home »

Atezolizumab Added to Chemo and PARP Inhibitor Shows No Benefit in Recurrent Ovarian Cancer

Oct 25, 2023

REFERENCES & ADDITIONAL READING

Monk BJ, Colombo N, Oza AM, et al. Lancet Oncol. 2021;22(9):1275-1289. DOI: 10.1016/S1470-2045(21)00342-9

 

Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Lancet Oncol. 2021;22(7):1034-1046. DOI: 10.1016/S1470-2045(21)00216-3

 

Moore KN, Bookman M, Sehouli J, et al. J Clin Oncol. 2021;39(17):1842-1855. DOI: 10.1200/JCO.21.00306

 

Kurtz JE, Pujade-Lauraine E, Oaknin A, et al. J Clin Oncol. 2023;41(30):4768-4778. DOI: 10.1200/JCO.23.00529

 

Gonzalez Martin A, Rubio Perez MJ, Heitz F, et al. Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial. Abstract LBA37, ESMO 2023, 20-24 October, Madrid, Spain.

 

Harter P, Trillsch F, Okamoto A, et al. J Clin Oncol. 2023;41(suppl 17):LBA5506. DOI: 10.1200/JCO.2023.41.17_suppl.LBA5506

 

Drew Y, Penson RT, O’Malley DM, et al. Annals of Oncology. 2020;31(suppl_4):S615-S616. DOI: 10.1016/j.annonc.2020.08.953

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement